Celltech rises on encouraging test results
Wednesday 10 May 1995
Clinical trials for three promising new medical compounds are continuing to go well for Celltech, the biotechnology company, which floated at 250p nearly 18 months ago.
The encouraging progress, combined with news that interim losses have been cut by £300,000 to £4.1m, was well received by the stock market, which marked up Celltech's shares by 2.5p to 307p yesterday.
Peter Fellner, chief executive, said: "The trials are very much on track and there have been no unpleasant surprises as some others in the sector have had." The second phase of studies to determine whether the compounds actually work is now under way, he said.
None of the expected side-effects have shown up in a new oral treatment for mild and moderate asthma, code-named CDP 840, which could be submitted for licensing in 1998. The potential for the drug, being developed with Merck, should be clearer by the end of this year, Mr Fellner said. The market is huge, with $6bn being spent on existing products like Ventolin and Tilade last year.
But, if tests go well, Celltech's first approvals are likely to be for a drug being developed with Bayer to combat inflammatory bowel disorders, called CDP 571, and an anti-leukaemia compound that American Home Products is backing, entitled CDP 771. Mr Fellner said filings could come as early as 1997.
Celltech differentiates itself from other recent biotechnology offerings by its higher levels of external income. Turnover from its business making antibodies for groups like Roche and Johnson & Johnson rose from £6.5m to £7.2m in the six months to March. With interest income - £900,000 in the half-year, down from £1m before - that is meant to fund half the research and development budget, with the rest coming from big drug company partners. Mr Fellner was pleased with the fall in half-year losses, despite having raised R&D spending by £1m to £8.8m last year.
Harry Potter actor suffered 'severe flu-like symptoms' on a flight from London to Orlando
First full-length look is finally here
World cities ranked in terms of safety, food security and 'liveability'
- 1 Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
- 2 The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
- 3 Ball pool for adults opens in London
- 4 Amal Clooney gives excellent response to fashion question at European Court of Human Rights
- 5 Baldness could soon be treated using stem cells, scientists hope
Woman falls to her death as she celebrates marriage proposal at the edge of Ibiza cliff
Sex abuse inquiry: 'Victims receive death threats' after MPs release names online
Saudi preacher who 'raped and tortured' his five -year-old daughter to death is released after paying 'blood money'
Teenager brandishing fake gun taken down by police after demanding airtime on Netherlands' NOS TV station
The awkward moment Sarah Palin raised $25,000 for Hillary Clinton's election campaign
9 reasons Greece's experiment with the radical left is doomed to failure
'We would evict Queen from Buckingham Palace and allocate her council house,' say Greens
Have we reached 'peak food'? Shortages loom as global production rates slow
Greece elections: Syriza and EU on collision course after election win for left-wing party
British grandmother Lindsay Sandiford faces execution by firing squad in Indonesia
Liberal Democrat minister defends comments suggesting immigration causes pub closures
iJobs Money & Business
£30000 - £35000 per annum + Benefits: Ashdown Group: Marketing Manager - Marke...
£13000 per annum: Recruitment Genius: This Pension Specialist was established ...
£23000 - £26000 per annum + Benefits: Ashdown Group: Market Research Executive...
£25000 - £35000 per annum: Recruitment Genius: A Technical Report Writer is re...